What is Synthex?
Synthex is a biotechnology firm specializing in drug discovery through target-centric cell-based functional selection. Their proprietary ToR platform is engineered to identify rare and selective drugs capable of modulating challenging protein targets and exploring novel therapeutic mechanisms. This innovative approach aims to accelerate the development of next-generation therapeutics for complex diseases, serving the pharmaceutical and biotechnology sectors.
How much funding has Synthex raised?
Synthex has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for Synthex?
With its recent major strategic investment, Synthex is poised for accelerated growth and further development of its innovative drug discovery platform. The large-scale, late-stage funding context suggests a focus on scaling operations, expanding clinical trials, and potentially forging strategic partnerships to bring novel therapies to market. This capital infusion will likely enable Synthex to tackle more ambitious targets and solidify its position as a leader in precision medicine.
See full Synthex company page
